You need AI to improve productivity. But AI does not take out responsibilities especially in regulated industries. In drug discovery and big pharmaceuticals, AI will improve workflows, but AI outputs must still be evaluated by humans.
Redouble AI (redouble.ai) scales human-in-the-loop for AI workflows in regulated industries. Simply, it improves the efficiency of human elements in reviewing the outputs of AI systems: “Instead of having to rely on slow and expensive human reviewers, Redouble’s clients save 80% of staff costs and significantly improve the accuracy and quality of their outputs by integrating our tool into their workflows.”
The team includes a medical doctor and an Oxford PhD, ex-AI drug discovery startup founder, ex-CEO of a small pharma and ex-Novartis engineer, providing the star nexus to execute the complex mission.
Tekedia Mini-MBA edition 16 (Feb 10 – May 3, 2025) opens registrations; register today for early bird discounts.
Tekedia AI in Business Masterclass opens registrations here.
Join Tekedia Capital Syndicate and invest in Africa’s finest startups here.
The foundation stack of their product will work for securities and the broad capital market even as they’re starting in drug discovery and pharma. Tekedia Capital (capital.tekedia.com) welcomes Redouble AI to our community, and asks companies in this industry to schedule demos with the company. They’re growing rapidly because Redouble AI is bringing order in the fledgling AI sector in pharma and making drugs.
---
Register for Tekedia Mini-MBA (Feb 10 - May 3, 2025), and join Prof Ndubuisi Ekekwe and our global faculty; click here.